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Abstract
Background: CHEK2*1100delC is a moderate-risk breast cancer susceptibility allele with a high prevalence in the
Netherlands. We performed copy number and gene expression profiling to investigate whether CHEK2*1100delC
breast cancers harbor characteristic genomic aberrations, as seen for BRCA1 mutated breast cancers.
Methods: We performed high-resolution SNP array and gene expression profiling of 120 familial breast carcinomas
selected from a larger cohort of 155 familial breast tumors, including BRCA1, BRCA2, and CHEK2 mutant tumors.
Gene expression analyses based on a mRNA immune signature was used to identify samples with relative low
amounts of tumor infiltrating lymphocytes (TILs), which were previously found to disturb tumor copy number
and LOH (loss of heterozygosity) profiling. We specifically compared the genomic and gene expression profiles of
CHEK2*1100delC breast cancers (n = 14) with BRCAX (familial non-BRCA1/BRCA2/CHEK2*1100delC mutated) breast
cancers (n = 34) of the luminal intrinsic subtypes for which both SNP-array and gene expression data is available.
Results: High amounts of TILs were found in a relatively small number of luminal breast cancers as compared to breast
cancers of the basal-like subtype. As expected, these samples mostly have very few copy number aberrations and no
detectable regions of LOH. By unsupervised hierarchical clustering of copy number data we observed a great degree
of heterogeneity amongst the CHEK2*1100delC breast cancers, comparable to the BRCAX breast cancers. Furthermore,
copy number aberrations were mostly seen at low frequencies in both the CHEK2*1100delC and BRCAX group
of breast cancers. However, supervised class comparison identified copy number loss of chromosomal arm 1p
to be associated with CHEK2*1100delC status.
Conclusions: In conclusion, in contrast to basal-like BRCA1 mutated breast cancers, no apparent specific somatic copy
number aberration (CNA) profile for CHEK2*1100delC breast cancers was found. With the possible exception of copy
number loss of chromosomal arm 1p in a subset of tumors, which might be involved in CHEK2 tumorigenesis.
This difference in CNAs profiles might be explained by the need for BRCA1-deficient tumor cells to acquire survival
factors, by for example specific copy number aberrations, to expand. Such factors may not be needed for breast
tumors with a defect in a non-essential gene such as CHEK2.
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Background
Approximately 10–15 % percent of all breast cancer
cases arise within a familial clustering of multiple
breast cancer cases. Inherited germ-line mutations in
the high risk genes BRCA1, BRCA2, and PALB2 are
identified in approximately 20 percent of these breast
cancer families. In addition, mutations in the CHEK2,
ATM and BRIP1 genes confer a moderate lifetime risk
of breast cancer but are rare and account for less
than 5 % of familial breast cancer cases [1, 2].
CHEK2*1100delC is a moderate-risk breast cancer
susceptibility allele with a relatively high prevalence
in the Netherlands of 1.1 % in the general population,
2.5 % in unselected breast cancer cases, and 4.9 % in
familial breast cancer cases. Other mutations in the
CHEK2 gene contributing to breast cancer risk are
negligible in the Dutch population. The lifetime risk
of breast cancer for a female CHEK2*1100delC muta-
tion carrier from the general population is 20–25 %,
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increasing to 35–45 % in a familial breast cancer set-
ting [3–5].
CHEK2 (Checkpoint kinase 2) has been shown to be
involved in cell cycle control and DNA damage re-
sponse. ATM (Ataxia telangiectasia mutated) phos-
phorylates CHEK2 in response to DNA damage,
resulting in CHEK2 homodimerization. The resulting
active kinase exerts its function through its ability to
phosphorylate TP53, CDC25A, CDC25C, PLK and
BRCA1 [6]. The function of CHEK2 is abrogated by
the 1100*delC frameshift mutation which causes a
premature translation stop in the kinase domain of
the protein. Both the mRNA, which is degraded
through nonsense-mediated mRNA decay, as well as
the resulting truncated protein are highly unstable [7, 8].
Very few breast tumors from 1100delC carriers show
CHEK2 protein expression although LOH of the wild-
type allele is infrequently found [9]. In contrast, LOH
of the BRCA1 gene is frequently reported in BRCA1-
mutated breast cancers [10]. Also, BRCA1 mutated
breast tumors are frequently reported to be of the
basal-like intrinsic subtype, opposed to breast tumors
from CHEK2 mutation carriers, which are reported to
be mostly steroid hormone receptor positive (proges-
terone receptor/progesterone receptor (ER/PR) posi-
tive) [11]. In accordance, gene expression profiling
assigns tumors from CHEK2 mutation carriers to the
luminal intrinsic subtypes [12].
We and others have shown specific somatic pro-
files of CNAs characteristic for both BRCA1 and
BRCA2-associated breast carcinomas [13–17]. These
CNAs are thought to reflect specific oncogenic path-
ways in tumor development. The identification of
driver genes in these genomic regions could lead to
a better understanding of the underlying process of
tumorigenesis and may provide novel clues for targeted
therapies.
In this study we have performed high-resolution copy
number, LOH and gene expression profiling of 120 fa-
milial breast carcinomas selected from a larger cohort
of 155 familial breast tumors, including BRCA1, BRCA2
and CHEK2 mutant tumors. Samples were selected for
low amounts of tumor infiltrating lymphocytes (TILs)
by mRNA profiling because TILs have detrimental ef-
fects on genomic profiling of tumor material [18]. To
ascertain whether CHEK2*1100delC breast cancers harbor
characteristic genomic aberrations, as seen in BRCA1 mu-
tated breast cancers, we specifically compared the gen-
omic profiles of 14 CHEK2*1100delC breast cancers and
34 BRCAX breast cancers of the luminal intrinsic sub-
types for which both SNP-array and gene expression data
is available. We compared our results with previously re-
ported findings on genomic and gene expression profiling
of CHEK2*1100delC breast cancers [19].
Methods
Ethics statement
This study has been approved by the medical ethical
committee at Erasmus MC, and was performed accord-
ing the Code of Conduct of the Federation of Medical
Scientific Societies in The Netherlands. Anonymous or
coded use of redundant tissue for research purposes is
part of the standard treatment agreement with patients
in our hospitals, and informed consent was therefore
not required [20].
Sample collection
Fresh-frozen specimens of primary breast tumors
from female familial breast cancer cases were selected
from the tissue bank of the Erasmus Medical Center
Rotterdam. All cases had been screened for germ line
mutations in BRCA1, BRCA2 and for the CHEK2*1100-
delC mutation. The complete breast cancer cohort con-
sists of 155 primary tumors and includes 26 tumors with a
CHEK2*1100delC mutation, 47 BRCA1-mutated tumors,
6 BRCA2-mutated tumors, and 76 BRCAX tumors. These
BRCAX breast cancer cases all originated from families
with at least two breast cancer cases in first or second de-
gree relatives of which at least one had been diagnosed be-
fore the age of 60. The entire cohort has been described in
detail [12, 18]. In this study, 120 tumor samples for which
both SNP array and gene expression data is available were
used for further analyses. The gene expression and SNP
microarray data have been deposited in NCBI's Gene
Expression Omnibus and are accessible through GEO
Series accession number 54219.
Gene expression microarrays
For gene expression analysis. CEL files of the individual
samples as deposited in GEO 54219 were used. The data
was analyzed in Partek Genomics Suite (v6.6, Partek
Inc.). Detection of differential gene expression was per-
formed by ANOVA analysis, genes with FDR-stepup
(false discovery rate) p-values less than 0.05 were consid-
ered to be statistically significant differentially expressed.
Classification of intrinsic molecular subtypes
The intrinsic gene list was used to appoint the sam-
ples to molecular subtypes as described [12]. In short,
the intrinsic gene list [21] was mapped to the corre-
sponding probe-sets on the HGU_133_plus_2.0 array
using Unigene Cluster Id's. The most variable probe-
sets were used to cluster 120 familial samples using
average linkage hierarchical clustering with correlation
as a distance metric. In this paper, the luminal A and B
samples together are referred to as luminal samples.
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mRNA based sample selection
To select for samples with relative low number of TILs,
hierarchical clustering of expression data was used. This
approach has largely been described in our previous
work [18]. In short, the proportion of lymphocytic nuclei
of 96 tumor samples was assessed on H&E-stained fro-
zen sections. For subsequent mRNA analysis, the lu-
minal and basal samples were processed separately.
These samples were divided in two groups based on the
TIL percentages (high and low TIL count, median split)
on which subsequent ANOVA analysis was performed
to find differentially expressed probe sets passing a FDR
p-value <0.05. Finally, the overlapping probe-sets for the
luminal and basal sample sets were determined to create
the final mRNA immune signature, see Additional File
1. Following this approach, 14 out of a total of 17
CHEK2* 1100delC and 34 out of a total of 49 BRCAX
breast cancers with relative low levels of this expression
signature were selected for further supervised analyses.
Copy number analyses by SNP arrays
For copy number and LOH analyses, CEL files of the in-
dividual samples as deposited in GEO 54219 were used.
The array intensity. CEL files were processed by Partek
Genomics Suite using default settings for background
correction and summarization, results were corrected
for GC-content and fragment length. Unpaired copy
number analysis was performed in Partek Genomics
Suite, comparing signal Log2 ratios to a custom created
reference baseline of 90 female HapMap samples with
European ancestry (CEU). The genomic segmentation
algorithm was used to detect breakpoint regions and
estimate copy number levels with stringent parame-
ters (P < 0.0001, >20 markers, signal/noise: 0.45). With
an expected normal range of 2 ± 0.25 copies. Differ-
ences between the tumor groups (mutation class) for
frequency of copy number aberrations (gained, lost,
or unchanged) were calculated by employing a 3 x 2
Fisher’s exact test (FE). Resulting p-values were not
directly corrected for multiple testing. SNP array,
gene and cytogenetic band locations are based on the
hg19 Genome build. For unsupervised hierarchical
clustering of copy number data the called copy num-
ber states (amplification (copy number >6), gain, loss
or neutral) of the segmentation data were used as dis-
tance metric. Agglomerative clustering was performed
on these data by Euclidean distance and Wards method.
LOH calling by detection of allelic imbalance
A segmentation based approach of allelic imbalances
was used to identify regions of LOH. The B-allele fre-
quencies of the breast tumor samples were generated in
Partek Genomics Suite. Mirrored B-allele frequency
(mBAF) profiles were used as previously described [22].
The resulting mBAF profiles were segmented in Partek
Genomics Suite and LOH calling of segmented regions
was done by applying a fixed allelic imbalance threshold
of 0.76 and p-value <0.01. The same parameters used in
segmentation of the copy number data were applied, ex-
cept that a window size of 100 SNPs instead of 20 SNPs
was used as a minimum number of genomic markers.
Results
Sample selection for low amount of TILs
To select for samples with low number of TILs, hier-
archical clustering of expression data of all 120 breast
carcinomas based on the mRNA immune signature
was used (Fig. 1a). Relative high numbers of TILs
were predominantly found in basal-like breast cancers.
However, 14 BRCAX and three CHEK2*1100delC
samples of the luminal breast cancers were also found
to have such high mRNA signature values and were
not used in supervised class comparison of CNAs and
differential gene expression analysis. Fig. 1b shows the
correlation between immune signature mRNA values
and TIL percentages as determined on H&E stained
slides (rs = 0.74, p-value < 0.001).
Copy number and LOH profiling
High resolution copy number and LOH profiling by
means of SNP array analysis was performed to gain
insight into the genomic characteristics of CHEK2*1100-
delC as compared to BRCAX breast cancers. Intrinsic
sub-typing of breast carcinomas based on global gene
expression profiles has revealed large differences be-
tween the basal-like, ERBB2/Her2Neu and luminal
subtypes regarding patterns of CNA's [13, 23–25]. As
CHEK2*1100delC breast cancers are found to be ex-
clusively of the luminal subtypes [12], the analyses
were restricted to these intrinsic subtypes to avoid
subtype associated confounding effects on copy num-
ber profiling.
Unsupervised hierarchical clustering of copy number
profiles of all luminal CHEK2*1100delC and BRCAX
samples, i.e. including samples with high TILs, sug-
gests a great degree of heterogeneity amongst the
CHEK2*1100delC breast cancers comparable to that
seen in the BRCAX breast cancers (Fig. 2). The copy
number aberration clustering roughly divides the sam-
ples into three groups, as indicated in Fig. 2. In group
1 many tumors are seen to have similar CNAs, in-
cluding regions of copy number gain of chromosomal
arms 1q, 8q, and 16p and copy number losses of
chromosomal arms 8p and 16q. A second group
(group 2) of tumors was found to have a more un-
stable CNA profile with focal amplifications on
chromosome 17 (ERBB2) and concomitant high gene
expression values for ERBB2 and nearby genes (GRB7,
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Fig. 2 Genomic profiles of CHEK2*1100delC and BRCAX breast tumors. Hierarchical clustering of CNA data. On the vertical axis, chromosomes 1
to X are displayed. Copy number gains are indicated in dark red (copy number amplifications (copy number > 6) in light red), losses in blue, and
copy neutral regions in grey. TIL (black: high TIL, grey: low TIL) and mutation status (green: CHEK2*1100delC, grey: BRCAX) are indicated for each
sample in the top rows by color
Fig. 1 Hierarchical clustering of immune signature mRNA data and correlation with TILs. a, hierarchical clustering of mean centered, standardized
immune signature gene expression data. Samples in the blue branch are regarded as high TIL (red: relative high expression, green: relative low
expression), and are discarded from further analyses. Top row indicates mutation status (red: BRCA1, blue: BRCA2, green: CHEK2, grey: BRCAX), bottom
row indicates intrinsic subtype (grey: luminal, black: basal). b, correlation plot for immune signature mRNA values and TIL percentages as determined
by an experienced pathologist (rs = 0.74, p-value < 0.001), colors represent mutation status
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STARD3), while a third group (group 3) is character-
ized predominantly by high TIL samples with very
few CNAs. In agreement with the copy number ana-
lysis results, heterogeneous patterns of LOH with no
frequent reoccurring regions were identified (data not
shown).
Supervised class comparison of the copy number
profiles of low TIL CHEK2*1100delC (n = 14) and
BRCAX (n = 34) breast cancers identified a small
number of genomic regions with differential CNAs
(Fig. 3). Most notable is the copy number loss of
chromosome 1p which overlaps with a previously re-
ported region [19]. However, most of the identified
regions are marginally statistically significant and have
CNAs at very low frequencies in the two tumor
groups. Interestingly, a small region of (focal) copy
number gain on chromosome 17 (including the ERBB2
locus) is found in almost half (6/14) of the CHEK2*1100-
delC breast cancers.
Copy number losses on chromosome 22 (including the
CHEK2 locus) are found in half of the CHEK2*1100delC
breast cancers, of which 4 showed LOH at the CHEK2
locus. However, copy number losses on chromosome 22
are also frequently found for the BRCAX breast cancers
(25 % of the cases). Furthermore, samples with copy
number losses on chromosome 22 were seen in all 3
groups as identified by unsupervised hierarchical cluster-
ing of copy number data.
Gene expression analysis
Gene expression analysis by means of ANOVA was
restricted to low TIL samples of the luminal intrinsic
subtypes, with mutation status as single factor (14
CHEK2*1100delC vs. 34 BRCAX). This resulted in 6
differentially expressed probe-sets passing a step-up
FDR p-value of 0.05 (See Table 1). None of the differen-
tially expressed genes between the CHEK2*1100delC and
BRCAX breast cancers were found to overlap with the
CHEK2 signature reported by Muranen et al. [19].
Discussion
We performed high-resolution copy number, LOH and
gene expression profiling of CHEK2*1100delC breast
cancers to better understand the tumorigenesis to which
the germ line CHEK2 deficiency predisposes. Our ana-
lysis was restricted to breast cancers of the luminal in-
trinsic subtypes as CHEK2*1100delC breast cancers are
found to be exclusively of these mRNA based subtypes.
Furthermore, samples were selected for low numbers of
TILs based on a mRNA immune signature.
The copy number profiles of CHEK2*1100delC breast
carcinomas were found to be heterogeneous and largely
resemble those of the BRCAX breast carcinomas. The
largest group of tumors has characteristic copy number
gains of chromosomal arms 1q, 8q and 16p and copy
number losses of chromosomal arms 8p and 16q. These
CNAs have frequently been reported for breast
Fig. 3 Copy number frequency plots of 14 CHEK2*1100delC and 34 BRCAX low TIL breast tumors. a, the frequency (x-axis) of gains (red)
and losses (blue) are displayed along chromosomes 1 to X (y-axis) for 14 CHEK2*1100delC (top panel) and 34 BRCAX (bottom panel)
breast cancers. b, Fisher's exact test is used to determine regions of differential copy number aberrations between the CHEK2*1100delC
and BRCAX breast cancers. The dotted line represents a p-value threshold of 0.05 (not corrected for multiple testing). The regions above
the threshold are considered to be significantly different between the groups. P-values are - log 10 transformed
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carcinomas of the luminal intrinsic subtypes [13, 23–25].
A second group was found to have a more unstable
CNA profile and focal amplifications of the ERBB2
genomic region. The observed focal amplifications of
the ERBB2 genomic region and the increase in gene
expression levels of the genes herein suggest that a
proportion of CHEK2*1100delC breast cancers could
be related to the ERBB2/Her2Neu intrinsic subtype. A
third group was found to be largely CNA devoid;
most of these samples were identified to have high
numbers of tumor infiltrating lymphocytes (TILs). In
previous work we identified a similar CNA devoid
group of (BRCA1-mutated) basal-like breast carcin-
omas, which proved to be caused by the presence of
large numbers of TILs in these samples.
Compared to the BRCA1 and BRCA2 profiles reported
in literature and our previous study, copy number aber-
rations are infrequently seen in CHEK2*1100delC breast
cancers. The most frequently observed aberrations in
CHEK2*1100delC breast cancers are those seen in many
breast cancers of the luminal intrinsic subtypes. Also,
hierarchical clustering showed a great degree of het-
erogeneity of copy number profiles amongst the
CHEK2*1100delC breast cancers, while BRCA1-mu-
tated breast cancers frequently co-cluster in hierarch-
ical cluster analysis [13].
Few characteristic CNAs for CHEK2*1100delC breast
cancers were found. In contrast to our BRCA1 profiling
results [18], most of these CNAs in CHEK2*1100delC
breast cancers are seen at very low frequencies and are
marginally statistically significant. With the exception
of copy number loss of chromosomal arm 1p, which
was found more frequently in CHEK2*1100delC breast
cancers. Furthermore, the observed copy number amplifi-
cations overlapping the ERBB2 gene in the CHEK2*1100-
delC samples fits well with the reported over-expression
of the ERBB2 gene in half of the CHEK2*1100delC homo-
zygous cases [26].
For the most part, our findings are comparable to pre-
viously reported findings on the genomic characteristics
of CHEK2*1100delC breast cancers by Muranen et al.
[19]. This includes the copy number loss of chromo-
somal arm 1p seen in CHEK2*1100delC breast cancers,
and LOH/loss at the CHEK2 locus in only part of the tu-
mors. In line with this, Suspitsin et al. concluded that
tumor-specific loss of the wild-type allele is not charac-
teristic for breast cancers arising in CHEK2 mutation
carriers as well as for other moderate risk genes. [27]. In
contrast, the reported copy number gains of the CHEK2
region in CHEK2*1100delC breast cancers were not ob-
served in our data, we only observed normal copy num-
ber and copy number losses.
In addition, genome wide gene expression analysis
identified a small number of genes to be differentially
expressed between CHEK2*1100delC and BRCAX breast
cancers, of which none overlap with the previously re-
ported CHEK2 gene expression signature by Muranen et
al [19]. Furthermore, only 2 genes are seen to overlap
with a reported 40-gene CHEK2 signature found in the
study by Nagel et al. [12]. This difference is most likely
due to sample selection criteria. Where our analysis is
restricted to low-TIL BRCAX and CHEK2*1100delC
mutated breast cancers of the luminal subtypes, Nagel et
al. performed their analysis on all hormone receptor
positive breast cancers, including high-TIL and BRCA1/
BRCA2 mutated samples. Furthermore, we applied a
stringent false discovery p_value cut-off of 0.05, opposed
to a FDR p_value of 0.25 by Nagel et al. Also, there
is no overlap in the CHEK2 gene signatures reported
by Muranen et al. and Nagel et al.
The most significant differentially expressed gene in
the 40-gene CHEK2 signature is the CHEK2 gene itself.
We found CHEK2 gene expression to be particularly
high in the high-TIL BRCAX samples, this could explain
why, after sample selection, we do not find the CHEK2
gene to be differentially expressed.
All differentially expressed genes in our analysis
were found to be relatively higher expressed in the
CHEK2*1100delC samples as compared to the BRCAX
samples, but were not found in genomic regions of copy
number gain in the CHEK2*1100delC samples. We found
no direct links between these differentially expressed
Table 1 Differentially expressed probe-sets between CHEK2a1100delC and BRCAX breast cancers




NCRNA00201 225786_at chr1q44 0.00339396 2.4
CENPJ 223513_at chr13q12.12 0.00339396 1.8
OGT 209240_at chrXq13 0.0208235 1.5
PRPF4B 202127_at chr6p25.2 0.0208235 2
PIKFYVE 213111_at chr2q34 0.0208235 1.5
NFYB 218127_at chr12q22-q23 0.0284964 1.58
Details for differentially expressed probe-sets between CHEK2a1100delC and BRCAX breast cancers
FDR (False Discovery Rate)
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genes and CHEK2 gene function, except for possibly the
CENPJ gene. This gene encodes a protein that belongs to
the centromere protein family. The protein plays a struc-
tural role in the maintenance of centrosome integrity and
normal spindle morphology [28]. Recently, CHEK2 has
been reported to be involved in the regulation of proper
mitotic spindle formation through phosphorylation of
BRCA1, hereby ensuring chromosomal stability [29].
For BRCA1 mutated breast cancers, specific CNAs
are reported. Complete loss of BRCA1 leads to severe
proliferation defects in normal cells, proving lethal dur-
ing embryonic development [30]. Therefore, it seems
likely that BRCA1-mutated cells acquire survival factors
that allow BRCA1-deficient tumor cells to expand.
CNAs are well known mechanisms to acquire such fac-
tors. For instance, in previous work we identified a re-
gion of copy number loss on chromosome 15q in all
BRCA1-mutated samples, which likely acts on the re-
ported BRCA1 associated loss of 53BP1 [31]. In con-
trast to BRCA1, CHEK2 deficiency is not lethal as
evidenced by CHEK2*1100delC homozygous carriers in
the population and the viability of Chek2 knockout
mice [32, 33]. Therefore, specific survival factors for
CHEK2 mutated cells are not required during tumori-
genesis if the wild type allele for CHEK2 is lost. How-
ever, it remains unclear to what extent loss of the wild
type allele of CHEK2 is necessary for tumorigenesis. Al-
though CHEK2*1100delC homozygous female carriers
are more susceptible to tumor development [26], ana-
lysis of tumors from CHEK2*1100delC heterozygous
carriers show a heterogeneous pattern of LOH/loss at
the CHEK2 locus. It remains uncertain whether this re-
flects two different tumor groups, i.e. one with
complete loss of wild type CHEK2 and thereby CHEK2
driven tumorigenesis and one without thereby repre-
senting sporadic tumors, or that loss of one CHEK2 al-
lele is sufficient to drive tumorigenesis. Furthermore,
loss of the CHEK2 wild type allele could be a non-
driver event.
Conclusions
In conclusion, in contrast to BRCA1/2 breast cancers,
no apparent predominant specific CNA profile nor ro-
bust gene expression profile for CHEK2*1100delC breast
cancers was found. This could in part result from the
small number of CHEK2*1100delC breast cancer sam-
ples used in this study. However, in our previous work,
an even smaller number of BRCA1-mutated basal-like
breast cancers proved sufficient to identify BRCA1-asso-
ciated CNAs. Nevertheless, we cannot exclude the possi-
bility that multiple different CHEK2 specific profiles do
exist. Larger sample sizes are needed to investigate this.
The results show no specific tumorigenic events re-
garding CHEK2 tumorigenesis, except for copy number
loss of chromosomal arm 1p. However, gene expression
analysis did not hint towards any potential driver genes
in this region. Further studies are needed to establish
whether this loss is indeed associated with CHEK2
breast tumors. Also, gene expression analysis identified a
very small number of differentially expressed genes be-
tween the CHEK2*1100delC and BRCAX breast cancers,
of which, except for possibly CENPJ, none seem to have
a putative role in CHEK2 related tumorigenesis based on
what is known in literature. This small number of differ-
entially expressed genes can also, in part, be due to the
small amount of CHEK2*1100delC samples used in the
analysis, and need to be validated.
Based on our previous work on BRCA1 tumors and
the current study on CHEK2 tumors we postulate a
model in which breast tumors with a defect in an essen-
tial gene such as BRCA1 or BRCA2, result in copy num-
ber profiles that reflect both the tumor subtype and
specific surviving factors while breast tumors with a de-
fect in a non-essential gene such as CHEK2, result in
copy number profiles that largely reflect the tumor
subtype. In this model the presence of a germ line
CHEK2*1100delC mutation might be regarded as an
accelerator of tumorigenesis leading to CNA profiles
comparable to that of luminal sporadic breast tumors.
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